Vivio system
Vivio system has been studied in 2 papers since 2025: 2 observational studies in people. The newest paper, Jul 18, 2025: “Noninvasive Screening for Elevated LVEDP and Health Status in Outpatients at Risk for Heart Failure”.
2 papers study it1 findingUpdated
“Among 2,040 screened patients (mean age 74 ± 8 years; 49.8% women; 64.6% with diabetes mellitus; and 34.9% with CKD), 38.5% had an elevated LVEDP.”
- 1 lab in 1 country
- Funders: Alnylam Pharmaceuticals and 7 more
- 1 of 1 finding with company ties
- Humans2
What is Vivio system linked with?
1Studies link Vivio system with 1 measure, most often left ventricular end-diastolic pressure (1 study).
Left ventricular end-diastolic pressure
upin humans1+39%
1 study
Left ventricular end-diastolic pressure
upin humans1+39%
Vivio system is associated with left ventricular end-diastolic pressure in humans (outpatients at risk for HF (diabetes mellitus, chronic kidney disease, or suspected HF)) (38.5%).
“Among 2,040 screened patients (mean age 74 ± 8 years; 49.8% women; 64.6% with diabetes mellitus; and 34.9% with CKD), 38.5% had an elevated LVEDP.”
Humansoutpatients at risk for HF (diabetes mellitus, chronic kidney disease, or suspected HF)49.8% womensn = 2,040
Noninvasive Screening for Elevated LVEDP and Health Status in Outpatients at Risk for Heart Failure
JACC. Advances